Retevmo (Selpercatinib)
Retevmo (Selpercatinib)
- Medicine Name: Retevmo
- Generic Name: Selpercatinib
- Dosage Form & Strength: Capsules: 40/80 mg
- Manufactured By: Eli Lilly and Company
- Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET fusion +Ve thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
- Severe hepatic adverse reactions occurred in patients treated with selpercatinib capsules. Monitor ALT and AST prior to initiating Selpercatinib, every 2 weeks during the initial 3 months, then monthly thereafter.
- Hypertension occurred in patients, including Grade 3 and Grade 4 hypertension. Monitor ALT and AST before initiating retevmo capsules, every 2 weeks during the initial 3 months, then monthly thereafter.
- Selpercatinib can cause concentration-dependent QT interval prolongation. Assess patients who are at significant risk of having QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure.
- Evaluate the QT interval more frequently when retevmo 40 mg capsules is concomitantly used with strong and moderate CYP3A inhibitors or medicines known to prolong QTc interval.
- Serious events including fatal hemorrhagic events can occur with selpercatinib. Permanently interrupt selpercatinib therapy in such patients who are with life-threatening or severe hemorrhage.
- Impaired wound healing may appear in patients who receive medicines that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, retevmo 80 mg capsules has the potential to adversely affect wound healing.
What documents are required to import Retevmo?
Retevmo (Selpercatinib) capsules can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of the respective country).
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Retevmo (Selpercatinib) capsule is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.
- Indian Pharma Network (IPN) facilitates the import of critical medications like Retevmo (Selpercatinib) globally, ensuring the named patient supply (NPS). IPN is the facilitator that provides essential support for:
- Availability of Retevmo (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka).
- Retevmo Available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc
- Determining Medicine Price.
- Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
- Ensuring 100% transparency.
Indian Pharma Network (IPN) can facilitate the supply of Retevmo (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable).
We assure quality and worldwide delivery as per the buyer’s specifications.
Indian Pharma Network is proficient in sourcing Retevmo from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide in countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
Indian Pharma Network (IPN) is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address. Your health and well-being are our top priorities
What is the Generic Name for the trade name drug Retevmo®?
Selpercatinib is Generic Name for the trade name drug Retevmo®.
What is the Manufacturer Name of Retevmo®?
Retevmo® is manufactured by Eli Lilly and Company.
Is Retevmo® approved by the FDA?
Yes, Retevmo® is approved by the FDA. Date of approval: May 8, 2020.
What is Retevmo®?
Retevmo is authorized for RET-positive metastatic non-small cell lung cancer (NSCLC) and advanced thyroid cancers.
What is the dosage and form of Retevmo® supplied?
Retevmo® is supplied as Capsules: 40/80 mg for oral administration.
What are the most common side effects due to Retevmo®?
Most common side effects due to Retevmo® include: lower platelet count, higher cholesterol levels, rash, lower salt (sodium) levels in the blood, constipation, lower calcium levels in the blood, dry mouth, diarrhea, higher creatinine levels (this measures kidney function), high blood pressure, tiredness and lower white blood cell count.
How much does Selpercatinib cost in India?
The selpercatinib cost in India is reasonable. In order to procure this kinase inhibitor authentically, you can call or WhatsApp +91-9650877511 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Retevmo®?
Store at 20-25°C (68-77°F); excursions between 15°C and 30°C (59°F to 86°F) are permitted.
What is the mechanism of action for Retevmo (Selpercatinib)?
Retevmo works by inhibiting the activity of RET proteins, which can drive the growth of cancer cells in certain types of cancers, including non-small cell lung cancer (NSCLC) and thyroid cancers.
What are the approved formulations of Retevmo?
Retevmo is available in both capsules and newly approved tablet forms. The tablets come in strengths of 40 mg, 80 mg, 120 mg, and 160 mg. The capsule form will remain available until the transition to tablets is complete
What are the new approved indications for Retevmo?
In addition to its previous indications, Retevmo is now also approved for the treatment of pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, and advanced or metastatic thyroid cancer with a RET gene fusion
Is Retevmo available in Asia?
Retevmo capsule is available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
How can I get a Retevmo capsule ?
Indian Pharma Network (IPN) can facilitate the supply of Retevmo (prescription medicine) to locations worldwide while adhering to legal requirements.
Are there any new studies supporting the use of Retevmo?
Recent studies have demonstrated the efficacy of Retevmo in treating patients with RET fusion-positive solid tumors, which include various types of cancers beyond lung and thyroid cancers.
What should patients know about transitioning from capsules to tablets?
Patients currently taking Retevmo capsules will need to transition to the tablet form once it becomes widely available. This change aims to provide more convenient dosing options and improve patient adherence to the treatment regimen
What is the mechanism of action for Retevmo (Selpercatinib)?
Retevmo works by inhibiting the activity of RET proteins, which can drive the growth of cancer cells in certain types of cancers, including non-small cell lung cancer (NSCLC) and thyroid cancers.
What are the approved formulations of Retevmo?
Retevmo is available in both capsules and newly approved tablet forms. The tablets come in strengths of 40 mg, 80 mg, 120 mg, and 160 mg. The capsule form will remain available until the transition to tablets is complete
What are the new approved indications for Retevmo?
In addition to its previous indications, Retevmo is now also approved for the treatment of pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, and advanced or metastatic thyroid cancer with a RET gene fusion
Is Retevmo available in Asia?
Retevmo capsule is available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
How can I get a Retevmo capsule ?
Indian Pharma Network (IPN) can facilitate the supply of Retevmo (prescription medicine) to locations worldwide while adhering to legal requirements.
Are there any new studies supporting the use of Retevmo?
Recent studies have demonstrated the efficacy of Retevmo in treating patients with RET fusion-positive solid tumors, which include various types of cancers beyond lung and thyroid cancers.
What should patients know about transitioning from capsules to tablets?
Patients currently taking Retevmo capsules will need to transition to the tablet form once it becomes widely available. This change aims to provide more convenient dosing options and improve patient adherence to the treatment regimen
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.